Clinical trials
Small Cell Carcinoma clinical trials
Below are recruiting small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 798 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT06773910RecruitingPhase 2
New drug combo vs standard care for limited-stage small cell lung cancer
This trial tests a new combination of drugs (atigotatug and nivolumab) against the standard drug durvalumab for people with limited-stage small cell lung cancer who have completed chemotherapy and radiation without the cancer getting worse. The goal is to see if the new combination works better at keeping the cancer from coming back.
Daphne, AlabamaAges 18 years+ - NCT06430437RecruitingPhase 3
Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07149649RecruitingPhase 2/Phase 3
Magnesium for advanced lung cancer
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
AarauAges 18 years+ - NCT06405230RecruitingPhase 1/Phase 2
Study of Immunotherapy Response in Returned Lung Cancer
This trial tests how well a new imaging method and lab-grown tumor models can predict response to immunotherapy in people with non-small cell lung cancer that has returned after initial surgery. Participants will receive standard immunotherapy, and researchers will study their tumor samples and scans.
LondonAges 30 years+ - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06648096RecruitingPhase 1/Phase 2
Testing afatinib for head and neck cancer in Fanconi anemia patients
This trial tests whether the targeted drug afatinib can shrink advanced head and neck cancers in people who also have Fanconi anemia. It is for patients whose tumors cannot be surgically removed and have not responded to or cannot have other standard treatments.
HanoverAges 18 years+ - NCT06663098RecruitingPhase 2
Atezolizumab and chemo again for relapsed small cell lung cancer
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Aviano (PN)Ages 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07091305RecruitingPhase 2
Study of a new drug with chemotherapy for limited-stage small cell lung cancer
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
ShanghaiAges 18–75 - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT05472948RecruitingPhase 2
Testing surufatinib plus immunotherapy with capecitabine for bowel cancer
This Phase 2 study tests a combination of anti-cancer drugs (surufatinib, immunotherapy, and capecitabine) to treat cancer that has spread to other parts of the body. It’s for people whose small intestine or appendix adenocarcinoma has progressed after earlier treatment, aiming to shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18–70 - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06095583RecruitingPhase 3
Toripalimab for limited-stage small cell lung cancer after chemoradiation
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
Harbin, HeilongjiangAges 18 years+ - NCT04868162RecruitingPhase 2
MRG003 for head and neck cancer after prior treatments
This trial tests MRG003, a cancer medicine, in people with recurrent or metastatic squamous cell carcinoma of the head and neck who have already tried and had trouble with standard treatments like platinum and anti–PD-1 therapy. It looks at whether the treatment can shrink the cancer and how safe it is.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05269485RecruitingPhase 1/Phase 2
Hypofractionated radiation for stage III lung cancer
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Hefei, AnhuiAges 18–70 - NCT06006169RecruitingPhase 2
Study of new drugs for head and neck cancer and other solid tumors
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06007729RecruitingPhase 2
A study of HS-20093 for head and neck cancer and other solid tumors
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
Hefei, AnhuiAges 18 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06719700RecruitingPhase 2
Chemo-radiation with two drugs for limited-stage small cell lung cancer
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07014202RecruitingPhase 2
Radiation therapy after chemo-immunotherapy for lung cancer
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell carcinoma?
- Yes. Clin2 currently lists 798 recruiting small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.